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Abstract
Background: The liver secretes very-low-density lipoproteins (VLDLs) and plays a key role in lipid metabolism. Plasma total
triglyceride (TG) level variations have been studied in patients with hepatitis C virus (HCV)-related chronic hepatitis (CH-C).
However, the results of these studies are variable. A homogenous assay protocol was recently proposed to directly measure
the TG content in VLDL (VLDL-TG) and VLDL remnants.
Methodology/Principal Findings: Using the assay protocol, we determined serum VLDL-TG levels in 69 fasting patients
with biopsy-proven HCV-related chronic liver disease and 50 healthy subjects. Patients were classified into stages F0–F4
using the 5-point Desmet scale. Serum total TG levels in patients with non-cirrhotic (F1–F3) CH-C did not demonstrate
significant differences compared with healthy subjects, but serum VLDL-TG levels did demonstrate significant differences.
Mean serum VLDL-TG levels tended to decrease with disease progression from F1 to F4 (cirrhosis). Compared with healthy
subjects, serum non-VLDL-TG levels significantly increased in patients with stages F2 and F3 CH-C; however, we observed no
significant difference in patients with liver cirrhosis. Furthermore, the serum VLDL-TG/non-VLDL-TG ratio, when taken,
demonstrated a significant decrease in patients with CH-C from the mildest stage F1 onward.
Conclusions/Significance: The decrease in serum VLDL-TG levels was attenuated by increase in non-VLDL-TG levels in
patients with non-cirrhotic CH-C, resulting in comparable total TG levels. Results of previous studies though variable, were
confirmed to have a logical basis. The decrease in the serum VLDL-TG/non-VLDL-TG ratio as early as stage F1 demonstrated
TG metabolic alterations in early stages of CH-C for the first time. The involvement of TG metabolism in CH-C pathogenesis
has been established in experimental animals, while conventional TG measurements are generally considered as poor
indicators of CH-C progression in clinical practice. The serum VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic
alterations, may be an early indicator of CH-C.
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Introduction
Plasma triglyceride (TG)-rich lipoproteins comprise a mixture of
lipoprotein species that are characterized by differences in density
and apolipoprotein composition. In the fasting state, plasma TGs are
predominantly transported by very-low-density lipoproteins (VLDLs)
secreted by the liver[1].Inthe fed state,plasma TGs are substantially
transported by VLDLs as well as chylomicrons (CMs) secreted by the
intestine. Because the liver plays a key roleinlipoprotein metabolism,
alterations in lipoprotein metabolism in hepatobiliary diseases may be
of practical as well as of theoretical interest.
In many countries, chronic hepatitis C virus (HCV) infection is
the leading cause of chronic hepatitis, liver cirrhosis, and
hepatocellular carcinoma. Interactions between chronic HCV
infection and lipid metabolism have been suggested. Some studies
indicate a higher prevalence of hypocholesterolemia [2] and
hypobetalipoproteinemia [3] in patients infected with HCV than
healthy subjects (controls). These changes may be more common
among patients infected with HCV genotype 3. These patients
develop hepatic steatosis more frequently than those infected with
other genotypes [2].
Furthermore, plasma TG level variations have been reported in
patients with HCV-related chronic hepatitis (CH-C) [2,4]. The
results of previous studies on plasma TG levels, however, are
variable. One report indicates significantly lower total plasma TG
levels in patients with CH-C than in non-HCV controls [4];
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17309however, it should be mentioned that patients in this study were
not confirmed by liver biopsy and 51% of these patients might
have significant fibrosis or cirrhosis [4]. In another report, total
TG levels in patients with biopsy-proven CH-C were comparable
to those in control subjects [2]. Hence, in CH-C clinical practices,
plasma TG level is not considered as a sensitive laboratory test.
However, experiments with animals and cultured cells have
established relationships between TG metabolism, HCV infection,
and CH-C. TG metabolism is not only affected by HCV infection
[5,6], but it also exerts an influence on HCV replication [7].
Because TGs in plasma are transported by a mixture of different
lipoprotein species, such as CMs, VLDLs, and VLDL remnants
[also called intermediate-density lipoproteins (IDLs)], selective
measurement of these TG-rich lipoproteins is essential to obtain
further insight into TG metabolic alterations under pathological
conditions.
Compared to low-density lipoprotein (LDL) and high-density
lipoprotein (HDL), technological difficulties have hampered
specific measurement of VLDL although TGs are transported
mainly by VLDL in the fasting state; these conditions differ from
those surrounding cholesterols. Cholesterols are transported
mainly by LDL [1], and specific measurement of cholesterol
content in LDL is a commonly-used laboratory test in clinical
practice.
To overcome these difficulties, Okada et al. [8] proposed a
homogenous assay protocol to directly measure the TG content in
VLDL and VLDL remnants. In the present study, we refer to this
measurement as VLDL-TG, conventional TG measurement as
total TG, and total TG minus VLDL-TG as non-VLDL-TG; thus
non-VLDL-TG includes TG content in CM (CM-TG), TG
content in LDL (LDL-TG) and TG content in HDL (HDL-TG).
We utilized this new method and evaluated these serum TG
profiles in biopsy-proven CH-C patients.
Methods
Ethics Statement
The study was approved by the Human Ethics Committee of
Chiba University. Written informed consent was obtained from all
the subjects. The Human Ethics Committee of Chiba University
also approved the use of residual sera collected during routine
laboratory sampling from the patients for the study, provided that
strict anonymity was maintained. The patient sera were
irrevocably anonymized and unlinked from the persons who
provided the sample.
Objectives
As mentioned in the Introduction section, it remains to be
established whether or not the serum total TG levels in patients
with CH-C are significantly lower than those in healthy subjects.
However, this fact appears unreasonable from the viewpoints that
the liver is a central organ for lipid metabolism and that total
cholesterol, which is a representative lipid in blood, is evidently
lower in patients with CH-C than in healthy subjects [2,4]. There
must be a rational explanation for this discrepancy. Thus, we
considered elucidating the explanations for this by investigating
the serum TG profile using the VLDL-TG method developed by
Okada et al. [8].
Participants
This study included 69 patients with untreated HCV-related
chronic liver disease who had been hospitalized for liver biopsy at
the Chiba University Hospital. The control group consisted of 50
apparently healthy, fasting subjects who had sought an annual
medical check-up at the Kashiwado Clinic. All subjects were
negative for hepatitis B surface antigen, and none had a history of
excessive alcohol drinking or drug abuse. In control subjects, anti-
HCV antibody test results were all negative and significant hepatic
steatosis was not found by ultrasonography. The characteristics of
patients and healthy subjects are summarized in Table 1.
Description of Procedures or Investigations Undertaken
Liver biopsies were performed with a Tru-Cut needle (14G)
under ultrasound guidance [9]. The biopsy specimens were
reviewed by two experienced hepatologists. Fibrosis staging was
evaluated based on the 5-point classification of Desmet et al. [10]
as follows: F0 (no fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis),
F3 (severe fibrosis), and F4 (cirrhosis) (Table 1). In 90% of cases,
the two hepatologists reached the same conclusion. When their
results were discordant, a third hepatologist made the final
determination.
At the time of the liver biopsy, venous blood was drawn after a
12-h overnight fast to determine blood chemistry values. Following
routine laboratory tests, serum total TG and VLDL-TG levels
were determined using residual sera. Serum total TG levels were
measured by a conventional enzymatic assay (Auto L Mizuho TG-
FR, Mizuho Medy, Tosu, Japan).
Serum VLDL-TG levels were determined using the surfactant-
based homogenous assay proposed by Okada et al. [8]. In this
assay protocol, two different nonionic surfactants, nonylphenol
ethoxylate (Emulgen 911) and alkylpolyoxyethylene (Tergitol NP-
10), were used to better differentiate VLDL and VLDL remnants
(IDL) from other lipoproteins. HCV genotype was evaluated using
the antibody serotyping method of Tsukiyama-Kohara et al. [11–
13]. In this serotyping assay, HCV serotypes 1 and 2 corresponded
to genotypes 1a/1b and 2a/2b, respectively, according to the
classification of Simmonds et al. [14]. When the results of the
serotyping assay were equivocal, PCR typing was conducted.
Patients whose serotypes were not classified as serotype 1 or 2 were
described as being of an unclassified type.
Statistical Methods
Values are presented as mean 6 SD (standard deviation). The
results were analyzed using the Mann-Whitney U-test for
comparisons between groups to determine their significance using
the 4-Step Excel Statistics software application (OMS Publishing
Inc., Tokorozawa, Japan, http://www.oms-publ.co.jp/index.html).
Significance levels were set at p,0.05.
Results
When comparisons were made between healthy subjects and
patients with non-cirrhotic CH-C (stages F1–F3), total TG levels
were similar (healthy subjects, 106.3654.8 mg/dl; CH-C patients,
96.4638.6 mg/dl; p=0.61), but serum VLDL-TG levels were
significantly lower (p=0.044) in patients with non-cirrhotic CH-C
(59.8629.4 mg/dl) than in healthy subjects (78.5648.9 mg/dl). In
contrast, serum non-VLDL-TG levels were significantly higher
(p,0.0001) in patients with non-cirrhotic CH-C (36.6613.1 mg/
dl) than in healthy subjects (27.8610.6 mg/dl). The differences
were more remarkable when serum VLDL-TG/non-VLDL-TG
ratios were compared (healthy subjects, 2.8761.56; CH-C
patients, 1.6560.68; p,0.000001).
With regard to the disease stages classified with the 5-point
Desmet scale, total TG levels in patients with CH-C did not
demonstrate any significant differences at any stage compared with
those in healthy subjects; however, a significant difference was
observed only when the liver disease progressed to liver cirrhosis
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significantly different not only in cirrhosis (F4) but also in stage
F3 of CH-C compared with those in healthy subjects (Figure 1).
Mean serum VLDL-TG levels demonstrated a tendency to
decrease with progression of liver disease from F1 to F4 (Figure 1),
while no significant differences were observed on comparing the
healthy subjects and patients with stages F1, F1 and F2, F2 and F3,
and F3 and F4 in the order of disease progression. In contrast,
serum non-VLDL-TG levels were significantly increased in
patients with stages F2 and F3 of CH-C compared to those in
healthy subjects; however, no significant changes were observed in
patients with liver cirrhosis (Figure 1).
As a result, serum VLDL-TG/non-VLDL-TG ratios were
significantly decreased in both early and advanced stages of HCV-
related chronic liver disease. Even in patients with the mildest
form of CH-C (F1), serum VLDL-TG/non-VLDL-TG ratios
alone were significantly different from those in healthy subjects
(Figure 1).
In the present study, the changes in serum VLDL-TG and non-
VLDL-TG levels were comparable between patients with HCV
genotype 1 and HCV genotype 2.
Discussion
The results of this study indicate that serum TG alterations,
evaluated as decreases in the serum VLDL-TG/non-VLDL-TG
ratio, occur as early as the stage F1 of CH-C. In contrast, no
statistically significant differences were observed in serum total TG
levels between healthy subjects and patients with stage F1 of CH-C
as well as between healthy subjects and patients with non-cirrhotic
CH-C (F1–F3).
Although it is known that the serum total TG level is decreased in
advanced chronic liver disease [15], alterations that occur in TG
metabolism in the early stages of HCV-related chronic liver disease
(such as non-cirrhotic CH-C) remain to be elucidated. Because TGs
in plasma are transported by a mixture of different lipoprotein
species, selective measurement of these TG-rich lipoproteins will
provide further insight into alterations of TG metabolism in liver
injury. Because of the heterogeneity of the non-VLDL component,
measurements of beta-lipoprotein levels will also be useful in
assessing the stages of HCV-related chronic liver diseases [3].
Several possible mechanisms could lower the serum VLDL-
TG/non-VLDL-TG ratio from the earliest stages of CH-C. Liver
disease resulting from HCV infection might impair VLDL
synthesis in hepatocytes. Previous studies with transgenic mice
revealed that the HCV core protein inhibits microsomal transfer
protein activity and causes impaired VLDL secretion [5,6].
Indeed, mean serum VLDL-TG levels decreased with progression
of liver disease from stages F1 to F4, and serum VLDL-TG levels
were found to be significantly lower in patients with stage F3 of
CH-C than those in healthy subjects (Figure 1).
The liver uptakes non-VLDL-TG in the form of free fatty acids
and glycerols produced by peripheral lipases and hepatic
triglyceride lipase [16] and in the form of lipoprotein particles
including LDL [17]. Lipoprotein lipase, a peripheral lipase,
preferentially hydrolyzes chylomicron-TG (CM-TG) and VLDL-
TG [16]. The activity of hepatic triglyceride lipase, which
preferably hydrolyzes HDL-TG [18,19] that constitutes consider-
able portion of non-VLDL-TG [1], is known to be decreased in
patients with parenchymal liver disease [20–22]. In addition,
hepatic triglyceride lipase also serves as a ligand that facilitates
uptake of lipoprotein particles including LDL [17]. Indeed, human
subjects who have deficient activity of hepatic triglyceride lipase
have increased plasma concentrations of HDL-TG and LDL-TG
[23–25]. These factors may comprise mechanisms that explain
why the serum non-VLDL-TG levels in stages F2 and F3 of CH-C
Table 1. Patient and healthy subject characteristics.
Characteristics Hepatitis C virus-related chronic liver disease Healthy subjects p-value
(n=69) (n=50)
Age (years) 60.4611.3 59.666.69 p=0.35
Sex (M/F) 32/37 27/23 p=0.41
BMI (Kg/m
2) 23.263.27 22.462.59 p=0.35
AST (IU/L) 52.0630.3 23.165.27 p,0.000000000001
ALT (IU/L) 46.6633.0 20.367.54 p,0.00000001
total CHO 156.2636.9 213.0628.8 p,0.000000000001
total TG 88.3637.0 106.3654.8 p=0.08
Serotype, n
Group 1 51
Group 2 13
Unclassified 5
Fibrosis, n
F0 0
F1 1 7
F2 1 0
F3 2 0
F4 2 2
p-values, when shown in italics such as p,0.01, indicate that there are significant differences. Values are shown as mean 6 SD
(standard deviation). BMI; Body Mass Index, AST; Aspartate transaminase, ALT; Alanine transaminase, CHO; cholesterol, TG;
triglyceride.
doi:10.1371/journal.pone.0017309.t001
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VLDL-TG levels was attenuated by the increase in serum non-
VLDL-TG levels, resulting in comparable serum total TG levels
between healthy subjects and patients with non-cirrhotic CH-C.
This means that serum total TG levels in patients with CH-C are
dominated by two factors.
In view of the above findings, the premise that ‘‘it remains to be
established whether or not the serum total TG levels in patients
Figure 1. Scatter plots of serum total TG, VLDL-TG, non-VLDL-TG levels, and VLDL-TG/non-VLDL-TG ratios. P-values are indicated as
the values between groups with bars. The mean value of each group is indicated at the bottom of each diagram. P-values, when indicated in bold
with an asterisk (such as 0.025*), indicate significant differences. SD; standard deviation.
doi:10.1371/journal.pone.0017309.g001
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is confirmed to have a logical basis. Furthermore, because of these
changes in serum VLDL-TG and non-VLDL-TG levels, serum
VLDL-TG/non-VLDL-TG ratios might indicate the clinical stage
of HCV-related chronic liver disease more accurately than serum
total TG or VLDL-TG levels alone.
When HCV-related liver disease progressed to stage F4, serum
non-VLDL-TG levels, being different from those in patients with
non-cirrhotic CH-C, did not demonstrate any significant differ-
ence when compared with those in healthy subjects (Figure 1).
This may mean that the increase in serum non-VLDL-TG levels
disappears when VLDL-TG secretion from the liver is consider-
ably decreased because LDL-TG, that constitutes substantial
portion of non-VLDL-TG, is generated from VLDL-TG released
from the liver [16]. Not all non-VLDL-TG is generated from
VLDL-TG. For example, CM is not generated from VLDL;
however, CM-TG production is negligible in the fasting state [1].
This concept is supported by the fact that the mean serum VLDL-
TG/non-VLDL-TG ratio in stage F4 CH-C (1.2660.54) was
lower than that in stage F3 (1.4660.52); the p-value between
patients with stage F4 and healthy subjects also was smaller than
that between patients with stage F3 and healthy subjects (Figure 1).
The involvement of TG metabolism in CH-C pathogenesis has
been established in experimental animals and cultured cells [5–7].
In contrast, conventional TG measurements are generally
considered as poor indicators of CH-C progression until the
end-stage of HCV-related chronic liver disease (cirrhosis). Our
study has demonstrated that the measurement of the serum
VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic
alterations during the development of HCV-related chronic liver
disease, may be an early indicator of CH-C.
Limitations
It should be noted that hepatic biopsy was not performed for the
healthy subjects, and thus their livers were not confirmed to be
completely normal. However, in control subjects, hepatitis B
surface antigen and anti-HCV test results were all negative and
their serum transaminase levels were within the reference intervals
(Table 1). In control subjects, significant hepatic steatosis was not
found by ultrasonography and none had a history of excessive
alcohol drinking or drug abuse. The patients and healthy subjects
in this study were from Japan, where HCV type 1 is the most
common genotype [26]. Because genotype 3 is almost undetected
in Japanese subjects, serum VLDL-TG/non-VLDL-TG ratios in
genotype 3 patients remain to be tested.
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